Kathryn A Phillips

List of Publications by Year
in descending order

129	4,939	94433	102487
papers	citations	37 h-index	66 g-index

129	129	129	5369
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Influence of payer coverage and outâ€ofâ€pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. Journal of Genetic Counseling, 2022, 31, 130-139.	1.6	13
2	US private payersâ€™ perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genetics in Medicine, 2022, 24, 238-244.	2.4	6
3	Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Affairs, 2022, 41, 383-389.	5.2	7
4	Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics, 2022, 40, 489-495.	3.3	5
5	Private payer coverage policies for ApoE-e4 genetic testing. Genetics in Medicine, 2021, 23, 614-620.	2.4	6
6	Availability and funding of clinical genomic sequencing globally. BMJ Global Health, 2021, 6, e004415.	4.7	37
7	Complicated legacies: The human genome at 20. Science, 2021, 371, 564-569.	12.6	11
8	Financing of germline testing: implications for availability and access. Molecular Genetics and Metabolism, 2021, 132, S330-S331.	1.1	0
9	Laboratory business models and practices: implications for availability and access to germline genetic testing. Genetics in Medicine, 2021, 23, 1681-1688.	2.4	3
10	Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. JAMA Health Forum, 2021, 2, e211428.	2.2	1
11	Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. Journal of Community Genetics, 2021, , 1.	1.2	1
12	Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genetics in Medicine, 2020, 22, 283-291.	2.4	41
13	Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. JAMA - Journal of the American Medical Association, 2020, 324, 2029.	7.4	24
14	Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value in Health, 2020, 23, 566-573.	0.3	32
15	Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy. Value in Health, 2020, 23, 527-528.	0.3	4
16	Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing. Value in Health, 2020, 23, 559-565.	0.3	6
17	Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value in Health, 2020, 23, 551-558.	0.3	9
18	Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencingâ€“Based Tests: Challenges, Opportunities, and Potential Solutions. Value in Health, 2020, 23, 540-550.	0.3	27

#	Article	IF	Citations
19	Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 866-872.	4.9	14
20	Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genetics in Medicine, 2019, 21, 152-160.	2.4	29
21	A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 214-221.	1.0	7
22	Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA - Journal of the American Medical Association, 2019, 321, 2403.	7.4	17
23	Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?. Personalized Medicine, 2019, 16, 365-367.	1.5	0
24	Insurance coverage for genomic tests. Science, 2018, 360, 278-279.	12.6	18
25	Evolving Payer Coverage Policies on Genomic Sequencing Tests. JAMA - Journal of the American Medical Association, 2018, 319, 2379.	7.4	21
26	Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genetics in Medicine, 2018, 20, 1544-1553.	2.4	25
27	New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare. JCO Precision Oncology, 2018, 2, 1-5.	3.0	3
28	Genetic Test Availability And Spending: Where Are We Now? Where Are We Going?. Health Affairs, 2018, 37, 710-716.	5.2	166
29	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health, 2018, 21, 1062-1068.	0.3	19
30	Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value in Health, 2018, 21, 1054-1061.	0.3	13
31	Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value in Health, 2018, 21, 1031-1032.	0.3	9
32	Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. Value in Health, 2018, 21, 1033-1042.	0.3	52
33	The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. The Journal of Precision Medicine, 2018, 4, .	0.0	6
34	â€œWhat Goes Around Comes Aroundâ€• Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value in Health, 2017, 20, 47-53.	0.3	18
35	Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value in Health, 2017, 20, 40-46.	0.3	17
36	Assessing the Value and Implications of Personalized/Precision Medicine and the â€œLessons Learnedâ€• for Emerging Technologies: An Introduction. Value in Health, 2017, 20, 30-31.	0.3	4

#	Article	IF	Citations
37	Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genetics in Medicine, 2017, 19, 1-11.	2.4	49
38	Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 219-228.	4.9	35
39	The price of whole-genome sequencing may be decreasing, but who will be sequenced?. Personalized Medicine, 2017, 14, 203-211.	1.5	7
40	EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. International Journal of Technology Assessment in Health Care, 2017, 33, 534-540.	0.5	20
41	Payer coverage policies for multigene tests. Nature Biotechnology, 2017, 35, 614-617.	17.5	42
42	Payer decision making for next-generation sequencingâ€“based genetic tests: insights from cell-free DNA prenatal screening. Genetics in Medicine, 2017, 19, 559-567.	2.4	19
43	Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Affairs, 2016, 35, 647-653.	5.2	11
44	What are people willing to pay for whole-genome sequencing information, and who decides what they receive?. Genetics in Medicine, 2016, 18, 1295-1302.	2.4	21
45	Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genetics in Medicine, 2016, 18, 111-116.	2.4	23
46	Challenges of Coverage Policy Development for Next-Generation Tumor Sequencing Panels: Experts and Payers Weigh In. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 311-318.	4.9	39
47	Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing. Technology and Health Care, 2015, 23, 373-379.	1.2	17
48	Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Personalized Medicine, 2015, 12, 13-22.	1.5	15
49	Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Medical Decision Making, 2015, 35, 734-744.	2.4	8
50	Potential public sector cost-savings from over-the-counter access to oral contraceptives. Contraception, 2015, 91, 373-379.	1.5	20
51	Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genetics in Medicine, 2015, 17, 314-315.	2.4	6
52	Availability and payer coverage of BRCA1/2 tests and gene panels. Nature Biotechnology, 2015, 33, 900-902.	17.5	22
53	Using the Coronary Artery Calcium Score to Guide Statin Therapy. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 276-284.	2.2	95
54	The economic value of personalized medicine tests: what we know and what we need to know. Genetics in Medicine, 2014, 16, 251-257.	2.4	91

#	Article	IF	Citations
55	Genomic Sequencing: Assessing The Health Care System, Policy, And Big-Data Implications. Health Affairs, 2014, 33, 1246-1253.	5.2	53
56	Barriers to insurance coverage of next-generation tumor sequencing by U.S. payers.. Journal of Clinical Oncology, 2014, 32, 6545-6545.	1.6	1
57	Economic Perspectives on Personalized Health Care and Prevention. Forum for Health Economics and Policy, 2013, 16, S23-S52.	0.8	14
58	Utilization of cardiac monitoring tests in women with nonmetastatic breast cancer treated with trastuzumab. Personalized Medicine, 2013, 10, 703-708.	1.5	0
59	Influence of Patient Preferences on the Cost-Effectiveness of Screening for Lynch Syndrome. Journal of Oncology Practice, 2012, 8, e24s-e30s.	2.5	18
60	Differences in US healthcare coverage policies inBRCAtesting and potential implications. Personalized Medicine, 2012, 9, 5-8.	1.5	4
61	User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives. Contraception, 2012, 86, 666-672.	1.5	19
62	Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer. Annals of Internal Medicine, 2011, 155, 69.	3.9	303
63	Women's out-of-pocket expenditures and dispensing patterns for oral contraceptive pills between 1996 and 2006. Contraception, 2011, 83, 528-536.	1.5	16
64	Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine, 2011, 13, 853-860.	2.4	19
65	Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 13-25.	4.9	31
66	Tradeoffs of Using Administrative Claims and Medical Records to Identify the Use of Personalized Medicine for Patients With Breast Cancer. Medical Care, 2011, 49, e1-e8.	2.4	21
67	Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Research and Treatment, 2011, 130, 619-626.	2.5	11
68	How does cost matter in health-care discrete-choice experiments?. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	1.7	50
69	Genomic Testing and Therapies for Breast Cancer in Clinical Practice. Journal of Oncology Practice, 2011, 7, e1s-e7s.	2.5	14
70	Health Technology Assessment and Private Payers' Coverage of Personalized Medicine. Journal of Oncology Practice, 2011, 7, 18s-24s.	2.5	44
71	Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genetics in Medicine, 2011, 13, 1045-1050.	2.4	36
72	Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Personalized Medicine, 2010, 7, 427-439.	1.5	10

#	Article	IF	Citations
73	Reply to Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer, 2010, 116, 3981-3981.	4.1	0
74	Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay. Journal of Oncology Practice, 2010, 6, 238-242.	2.5	51
75	Bringing evidence to the debate on abortion coverage in health reform legislation: findings from a national survey in the United States. Contraception, 2010, 82, 129-130.	1.5	6
76	A Standardized BCR-ABL Monitoring Test: Assessment of Potential Adoption Impacts In Healthcare In the United States. Blood, 2010, 116, 4754-4754.	1.4	21
77	How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a statedâ€choice survey. Health Economics (United Kingdom), 2009, 18, 1420-1439.	1.7	74
78	Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer, 2009, 115, 5166-5174.	4.1	64
79	Medicare formulary coverage for top-selling biologics. Nature Biotechnology, 2009, 27, 1082-1084.	17.5	12
80	Insured Women and Payment for Elective Abortion. Women's Health Issues, 2008, 18, 347-350.	2.0	0
81	Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice. JAMA - Journal of the American Medical Association, 2008, 300, 2542.	7.4	44
82	Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Current Opinion in Molecular Therapeutics, 2008, 10, 260-6.	2.8	26
83	Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends. Current Drug Safety, 2007, 2, 177-185.	0.6	54
84	Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Personalized Medicine, 2007, 4, 341-350.	1.5	11
85	Provider practice models for and costs of delivering medication abortion â€" evidence from 11 US abortion care settings. Contraception, 2007, 75, 45-51.	1.5	12
86	Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey. Value in Health, 2007, 10, 415-430.	0.3	128
87	Angiotensin Receptor Blockers on the Formularies of Medicare Drug Plans. Journal of General Internal Medicine, 2007, 22, 1172-1175.	2.6	8
88	Regulatory Perspectives on Pharmacogenomics: A Review of the Literature on Key Issues Faced by the United States Food and Drug Administration. Medical Care Research and Review, 2006, 63, 301-326.	2.1	20
89	Colorectal Cancer Screening. American Journal of Preventive Medicine, 2006, 30, 378-384.	3.0	17
90	Patient costs for medication abortion: Results from a study of five clinical practices. Women's Health Issues, 2006, 16, 4-13.	2.0	17

#	Article	IF	Citations
91	Initial development of an evidence base for personalized medicineâ€™s translation to clinical practice and health policy. Personalized Medicine, 2006, 3, 411-414.	1.5	6
92	Innovation in personalized medicine: BiDilÂ®as a case study for integrating clinical and policy developments. Personalized Medicine, 2006, 3, 421-427.	1.5	2
93	Diagnostics and biomarker development: priming the pipeline. Nature Reviews Drug Discovery, 2006, 5, 463-469.	46.4	104
94	The Intersection Of Biotechnology And Pharmacogenomics: Health Policy Implications. Health Affairs, 2006, 25, 1271-1280.	5.2	25
95	Novel personalized medicine technology:UGT1A1testing for irinotecan as a case study. Personalized Medicine, 2006, 3, 415-419.	1.5	6
96	Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997â€“2000. Annals of Internal Medicine, 2005, 142, 891.	3.9	219
97	Measuring the value of pharmacogenomics. Nature Reviews Drug Discovery, 2005, 4, 500-509.	46.4	88
98	Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm, 2005, 2, 1294-1300.	0.7	46
99	Generic Drug Savings. Annals of Internal Medicine, 2005, 143, 845.	3.9	1
100	Prescription drug dispensing limits and patterns. Managed Care Interface, 2005, 18, 41-6.	0.2	0
101	A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics, 2004, 5, 1139-1149.	1.3	101
102	Are Gatekeeper Requirements Associated with Cancer Screening Utilization?. Health Services Research, 2004, 39, 153-178.	2.0	43
103	Moving beyond the Typologies of Managed Care: The Example of Health Plan Predictors of Screening Mammography. Health Services Research, 2004, 39, 179-206.	2.0	19
104	The Effect of Area HMO Market Share on Cancer Screening. Health Services Research, 2004, 39, 1751-1772.	2.0	49
105	Selection Bias into Health Plans with Specific Characteristics: A Case Study of Endogeneity of Gatekeeper Requirements and Mammography Utilization. Health Services and Outcomes Research Methodology, 2004, 5, 103-118.	1.8	8
106	Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes and Control, 2004, 15, 883-892.	1.8	20
107	Out-of-pocket expenditures for oral contraceptives and number of packs per purchase. Journal of the American Medical Women's Association, 2004, 59, 36-42.	0.3	3
108	Willingness to recommend a health plan: who is dissatisfied and what don't they like?. American Journal of Managed Care, 2004, 10, 393-400.	1.1	3

#	Article	IF	Citations
109	Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. American Journal of Managed Care, 2004, 10, 425-32.	1.1	37
110	An experiment on simplifying conjoint analysis designs for measuring preferences. Health Economics (United Kingdom), 2003, 12, 1035-1047.	1.7	76
111	Willingness to use instant home HIV tests. American Journal of Preventive Medicine, 2003, 24, 340-348.	3.0	32
112	Important step forward in HIV-testing technolgies. American Journal of Preventive Medicine, 2003, 25, 167.	3.0	3
113	An introduction to cost-effectiveness and costâ€“benefit analysis of pharmacogenomics. Pharmacogenomics, 2003, 4, 231-239.	1.3	45
114	The Economics of Pharmacogenomics. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2003, 1, 277-284.	0.3	7
115	Impact of the U.S. panel on cost-effectiveness in health and medicine. American Journal of Preventive Medicine, 2002, 22, 98-105.	3.0	25
116	Measuring Preferences for Health Care Interventions Using Conjoint Analysis: An Application to HIV Testing. Health Services Research, 2002, 37, 1681-1705.	2.0	189
117	Measuring What People Value: A Comparison of "Attitude" and "Preference" Surveys. Health Services Research, 2002, 37, 1659-1679.	2.0	141
118	The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. Journal of the American College of Cardiology, 2001, 38, 1012-1017.	2.8	57
119	Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions. JAMA - Journal of the American Medical Association, 2001, 286, 2270.	7.4	598
120	Keeping Pace With Health System Change. Health Affairs, 2000, 19, 277-279.	5.2	0
121	The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. Aids, 2000, 14, 2159-2169.	2.2	35
122	Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci, 2000, 2, 80-90.	1.3	133
123	Health and Economic Benefits of Increased Î²-Blocker Use Following Myocardial Infarction. JAMA - Journal of the American Medical Association, 2000, 284, 2748.	7.4	94
124	HIV-1 Drug Resistance Genotyping. Pharmacoeconomics, 2000, 18, 425-433.	3.3	20
125	Continuing Screening Mammography in Women Aged 70 to 79 Years. JAMA - Journal of the American Medical Association, 1999, 282, 2156.	7.4	164
126	Willingness to pay for poison control centers. Journal of Health Economics, 1997, 16, 343-357.	2.7	48

#	Article	IF	Citations
127	Potential Use of Home HIV Testing. New England Journal of Medicine, 1995, 332, 1308-1311.	27.0	39
128	Speaking in Tongues: Integrating Economics and Psychology into Health and Mental Health Services Outcomes Research. Medical Care Review, 1992, 49, 191-231.	0.9	10
129	Informing and Educating the Electorate about AIDS. Medical Care Review, 1990, 47, 3-13.	0.9	3